Difficulty adhering to antidiabetic treatment: Factors associated with persistence and compliance

Diabetes and Metabolism

Volumn 39, Issue 3, 2013, Pages 250-257

  Guenette L ^a,b   Moisan, J ^a,b   Breton, M C ^b   Sirois, C ^c   Gregoire J P ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c UNIVERSITÉ DU QUÉBEC À RIMOUSKI   (Canada)

Author keywords

Adherence; Compliance; Determinants; Oral antidiabetic treatment; Persistence; Type 2 diabetes

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; GENERAL PRACTITIONER; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROCESS OPTIMIZATION; RURAL AREA; SOCIAL STATUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; QUEBEC;

EID: 84878769563     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.12.005     Document Type: Article

References (42)

1. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008, 32(suppl 1):S1-S201. Canadian Diabetes Association.
2. Wahl C., Gregoire J.P., Teo K., Beaulieu M., Labelle S., Leduc B., et al. Concordance, compliance and adherence in healthcare: closing gaps and improving outcomes. Healthc Q 2005, 8:65-70.
3. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf S.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
4. Balkrishnan R., Rajagopalan R., Shenolikar R.A., Camacho F.T., Anderson R.T. Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: an updated and expanded retrospective analysis. Curr Med Res Opin 2006, 22:551-559.
5. Boccuzzi S.J., Wogen J., Fox J., Sung J.C., Shah A.B., Kim J. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care 2001, 24:1411-1415.
6. Brown J.B., Nichols G.A., Glauber H.S., Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999, 21:1045-1057.
7. Catalan V.S., Couture J.A., LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med 2001, 161:1106-1112.
8. Dailey G., Kim M.S., Lian J.F. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001, 23:1311-1320.
9. Dailey G., Kim M.S., Lian J.F. Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002, 30:71-79.
10. Harley C.R., Mishra A., Cantor S.E., Nelson M., Walker A.M. A 'Real-World' analysis of persistence on and adherence to glipizide GITS, glipizide IR and glibenclamide in managed care among patients with type 2 diabetes mellitus. Clin Drug Investig 2002, 22:575-584.
11. Hertz R.P., Unger A.N., Lustik M.B. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005, 27:1064-1073.
12. Penning-van Beest F.J., van der Bij S., Erkens J.A., Kessabi S., Groot M., Herings R.M. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin 2008, 24:2523-2529.
13. Stephens J., Black B., Gold K., Botteman M., Pashos C., Walkinshaw C., et al. Persistence patterns with oral hypoglycemic agents in type 2 diabetes. J Clin Outcomes Manag 2002, 9:491-499.
14. van Dijk L., Heerdink E.R., Somai D., van Dulmen S., Sluijs E.M., de Ridder D.T., et al. Patient risk profiles and practice variation in nonadherence to antidepressants, antihypertensives and oral hypoglycemics. BMC Health Serv Res 2007, 7:51.
15. Grégoire J.P., Sirois C., Blanc G., Poirier P., Moisan J. Persistence patterns with oral antidiabetes drug treatment in newly treated patient: a population-based study. Value Health 2010, 13:820-826.
16. Perez N., Moisan J., Sirois C., Poirier P., Gregoire J.P. Initiation of insulin therapy in elderly patients taking oral antidiabetes drugs. CMAJ 2009, 180:1310-1316.
17. Colombi A.M., Yu-Isenberg K., Priest J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. J Occup Environ Med 2008, 50:535-541.
18. Donnan P.T., MacDonald T.M., Morris A.D. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002, 19:279-284.
19. Kalsekar I.D., Madhavan S.S., Amonkar M.M., Makela E.H., Scott V.G., Douglas S.M., et al. Depression in patients with type 2 diabetes: impact on adherence to oral hypoglycemic agents. Ann Pharmacother 2006, 40:605-611.
20. Kreyenbuhl J., Dixon L.B., McCarthy J.F., Soliman S., Ignacio R.V., Valenstein M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?. Schizophr Bull 2010, 36:428-435.
21. Melikian C., White T.J., Vanderplas A., Dezii C.M., Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002, 24:460-467.
22. Kilbourne A.M., Reynolds C.F., 3rd, Good C.B., Sereika S.M., Justice A.C., et al. How does depression influence diabetes medication adherence in older patients?. Am J Geriatr Psychiatry 2005, 13:202-210.
23. Evans J.M., Donnan P.T., Morris A.D. Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes. Diabet Med 2002, 19:685-688.
24. Karve S., Cleves M.A., Helm M., Hudson T.J., West D.S., Martin B.C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care 2008, 46:1125-1133.
25. Park K.-A., Kim J.-G., Kim B.-W., Kam S., Kim K.-Y., Ha S.-W., et al. Factors that affect medication adherence in elderly patients with diabetes mellitus. Korean Diabetes J 2010, 34:55-65.
26. Donnelly L.A., Morris A.D., Pearson E.R. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab 2009, 11:338-342.
27. Kalsekar I., Sheehan C., Peak A. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent). Res Social Adm Pharm 2007, 3:378-391.
28. Morningstar B.A., Sketris I.S., Kephart G.C., Sclar D.A. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther 2002, 27:213-220.
29. Rozenfeld Y., Hunt J.S., Plauschinat C., Wong K.S. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008, 14:71-75.
30. Venturini F., Nichol M.B., Sung J.C., Bailey K.L., Cody M., McCombs J.S. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother 1999, 33:281-288.
31. Florez H., Luo J., Castillo-Florez S., Mitsi G., Hanna J., Tamariz L., et al. Impact of metformin-induced gastrointestinal symptoms on quality of life and adherence in patients with type 2 diabetes. Postgrad Med 2010, 122:112-120.
32. Grégoire J.P., Moisan J., Guibert R., Ciampi A., Milot A., Gaudet M., et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol 2002, 55:728-735.
33. Grégoire J.P., Moisan J., Guibert R., Ciampi A., Milot A. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can J Cardiol 2006, 22:323-329.
34. Tamblyn R., Lavoie G., Petrella L., Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995, 48:999-1009.
35. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15:565-574.
36. Bonafede M.M., Kalsekar A., Pawaskar M., Ruiz K.M., Torres A.M., Kelly K.R., et al. A retrospective database analysis of insulin use patterns in insulin-naive patients with type 2 diabetes initiating basal insulin or mixtures. Patient Prefer Adherence 2010, 4:147-156.
37. Hess L.M., Raebel M.A., Conner D.A., Malone D.C. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006, 40:1280-1288.
38. Briesacher B.A., Andrade S.E., Fouayzi H., Chan K.A. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008, 28:437-443.
39. Tiv M., Viel J.F., Mauny F., Eschwege E., Weill A., Fournier C., et al. Medication adherence in type 2 diabetes: the ENTRED study 2007, a French Population-Based Study. PLoS One 2012, 7:e32412.
40. Friedman O., McAlister F.A., Yun L., Campbell N.R., Tu K. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario. Am J Med 2010, 123:173-181.
41. Pollack M.F., Purayidathil F.W., Bolge S.C., Williams S.A. Patient-reported tolerability issues with oral antidiabetic agents: associations with adherence; treatment satisfaction and health-related quality of life. Diabetes Res Clin Pract 2010, 87:204-210.
42. Balkrishnan R., Rajagopalan R., Camacho F.T., Huston S.A., Murray F.T., Anderson R.T. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003, 25:2958-2971.